Table 3.
Results of univariate and multivariate analysis of overall survival
| Variable | Univariate* | Multivariate† | ||
|---|---|---|---|---|
|
|
|
|||
| HR | p value | HR | p value | |
| Age (continuous) | 1.28 (1.18–1.40) | < 0.001 | 1.25 (1.10–1.43) | 0.001 |
|
| ||||
| Stage | — | < 0.001 | — | 0.003 |
|
| ||||
| II v. I | 1.28 (0.75–2.19) | 0.4 | 1.05 (0.49–2.24) | 0.9 |
|
| ||||
| III v. I | 3.02 (2.14–4.24) | < 0.001 | 2.00 (1.09–3.66) | 0.02 |
|
| ||||
| IV v. I | 7.18 (4.46–11.54) | < 0.001 | 3.61 (1.66–7.85) | 0.001 |
|
| ||||
| Residual disease (any v. none visible) | 3.98 (2.83–5.58) | < 0.001 | 2.53 (1.65–3.90) | < 0.001 |
|
| ||||
| Platinum-based chemotherapy | — | 0.002 | — | — |
|
| ||||
| Any v. none | 4.59 (1.46–14.4) | 0.009 | — | — |
|
| ||||
| Unknown v. none | 2.93 (0.89–9.63) | 0.08 | — | — |
|
| ||||
| Race (White v. other) | 0.65 (0.44–0.96) | 0.03 | 0.51 (0.28–0.92) | 0.02 |
HR = hazard ratio.
*
Number of complete observations: age 680, stage 644, residual disease 377, platinum-based primary chemotherapy 428, race 575.
†
Number of complete observations: 284.